Protalix BioTherapeutics Welcomes a New CFO
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a dynamic biopharmaceutical company dedicated to the development and commercialization of innovative recombinant therapeutic proteins, is excited to announce the appointment of Gilad Mamlok as the Senior Vice President and Chief Financial Officer. This strategic move signals a new chapter for the company as they prepare to expand their reach within the healthcare industry.
Experience and Leadership Transition
Mr. Mamlok brings three decades of valuable experience in the fields of healthcare and technology to Protalix. His previous roles include serving as the Chief Financial Officer at TytoCare Ltd., a company specializing in remote healthcare solutions. Moreover, his tenure at Sol-Gel Technologies Ltd. involved crucial involvement in initial public offerings and various capital markets initiatives. His expertise in business development and investor relations will be instrumental as Protalix navigates its growth strategy.
Recognition of Commitment
Dror Bashan, President and Chief Executive Officer of Protalix, expressed his enthusiasm about welcoming Mr. Mamlok, stating, "Gilad will play a pivotal role in executing our growth strategy." Bashan also paid tribute to the outgoing CFO, Eyal Rubin, acknowledging his dedication and significant contributions over the past six years. Eyal’s leadership was pivotal during a crucial time for the company, fortifying Protalix's financial foundation as they look towards future growth.
Educational Background of Gilad Mamlok
Mr. Mamlok’s strong academic foundation supports his extensive professional achievements. He holds a BA in Economics, graduating magna cum laude, alongside a Master’s degree in Business/Managerial Economics, both from Tel Aviv University. This educational background enhances his ability to navigate complex financial landscapes in the biopharmaceutical sector.
Protalix's Mission and Vision
At Protalix BioTherapeutics, the focus remains on advancing recombinant therapeutic proteins through the proprietary ProCellEx plant cell-based expression system. This innovative platform is not only revolutionary in protein production but is also the first of its kind to receive FDA approval for a plant cell-derived protein. With incident products targeting various therapeutic areas, Protalix is well-positioned for future success.
Commitment to Innovation
Protalix has made significant strides in its product development pipeline. With the current partnership established for the global commercialization of Elfabrio, and continued focus on other candidates such as PRX–115 and PRX–119 for treating several severe conditions, Protalix is committed to leveraging its unique technological advancements for the benefit of patients worldwide. The company remains focused on the significant potential of its innovative approach in addressing critical health challenges.
Frequently Asked Questions
What role will Gilad Mamlok play at Protalix?
Gilad Mamlok will serve as the Senior Vice President and Chief Financial Officer, overseeing financial strategies and business development.
Who did Gilad Mamlok succeed at Protalix?
Mr. Mamlok succeeds Eyal Rubin, who has played a significant role in the company's financial leadership.
What is Protalix BioTherapeutics known for?
Protalix is known for developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell expression system.
What products are currently in Protalix’s pipeline?
Protalix's pipeline includes products like PRX–115 and PRX–119, targeting various critical health challenges.
How does Protalix ensure its growth strategy?
Protalix is committed to innovation and strategic partnerships, focusing on expanding its product development and commercialization efforts.
